The "Inclusion Body Myositis - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.This report offers in-depth insights into the Inclusion Body Myositis (IBM) pipeline, ...

Abcuro Inc. said the new capital will be used to complete the registrational Phase 2/3 clinical trial of ulviprubart to treat inclusion body myositis (IBM). If the company sees positive results ...

Musician Peter Frampton shared some very exciting news on his social media: He officially has a service dog named Bigsby!

New research examining the skeletal muscle cells of patients with inclusion body myositis (IBM) has revealed that the nucleic acid-binding protein TDP-43, which is normally restricted to the ...

"IBM is a tremendously debilitating disease, which drastically and irreversibly reduces quality of life," commented Paula Eichenbrenner, executive director of The Myositis Association. "Exercise ...

Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that the ...

“We examined whether they were contributing to myositis phenotypes, or subgroups of myositis, as very few prior studies have addressed these exposures in patients with myositis. “An earlier ...

Myositis-specific autoantibodies (MSAs) are specific to patients with IIMs. Myositis-associated autoantibodies (MAAs) can also occur in dermatomyositis but is commonly seen in overlap with another ...

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors. Abcuro announced that it has obtained $200 million in Series C financing, led by ...

1 Centro Hospitalar de Entre o Douro e Vouga – Physical and Rehabilitation Medicine Department – Santa Maria da Feira, Portugal 2 Physical and Rehabilitation Medicine – Portugal Myositis ossificans ...